Tharimmune (THAR) Competitors $1.69 +0.04 (+2.42%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.64 -0.04 (-2.66%) As of 07/18/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. RVPH, HOTH, RLYB, QTTB, PRPH, ASBP, GELS, CASI, LPCN, and MTEXShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Reviva Pharmaceuticals (RVPH), Hoth Therapeutics (HOTH), Rallybio (RLYB), Q32 Bio (QTTB), ProPhase Labs (PRPH), Aspire Biopharma (ASBP), Gelteq (GELS), CASI Pharmaceuticals (CASI), Lipocine (LPCN), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Reviva Pharmaceuticals Hoth Therapeutics Rallybio Q32 Bio ProPhase Labs Aspire Biopharma Gelteq CASI Pharmaceuticals Lipocine Mannatech Reviva Pharmaceuticals (NASDAQ:RVPH) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings. Which has preferable earnings and valuation, RVPH or THAR? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.79-0.51TharimmuneN/AN/A-$12.20M-$7.88-0.21 Do analysts recommend RVPH or THAR? Reviva Pharmaceuticals presently has a consensus price target of $9.00, indicating a potential upside of 2,155.07%. Tharimmune has a consensus price target of $17.00, indicating a potential upside of 905.92%. Given Reviva Pharmaceuticals' higher possible upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media refer more to RVPH or THAR? In the previous week, Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score. Company Overall Sentiment Reviva Pharmaceuticals Neutral Tharimmune Neutral Is RVPH or THAR more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -302.31% Tharimmune N/A -489.33%-264.34% Do institutionals and insiders believe in RVPH or THAR? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 10.0% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, RVPH or THAR? Reviva Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. SummaryReviva Pharmaceuticals beats Tharimmune on 7 of the 12 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39M$2.95B$5.54B$9.40BDividend YieldN/A2.44%3.75%4.03%P/E Ratio-0.2119.7528.0119.79Price / SalesN/A298.31432.5697.34Price / CashN/A42.5936.1658.27Price / Book2.497.678.125.65Net Income-$12.20M-$55.28M$3.25B$257.91M7 Day Performance-2.31%4.85%1.64%3.35%1 Month Performance18.18%11.70%7.27%11.09%1 Year Performance-54.81%3.69%32.88%18.99% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.1996 of 5 stars$1.69+2.4%$17.00+905.9%-55.5%$4.39MN/A-0.212Gap UpRVPHReviva Pharmaceuticals2.6921 of 5 stars$0.39+2.8%$9.00+2,225.6%-63.0%$18.58MN/A-0.495Gap UpHOTHHoth Therapeutics2.4335 of 5 stars$1.40+7.3%$4.00+186.7%+40.4%$18.43MN/A-1.224RLYBRallybio2.6965 of 5 stars$0.44-13.8%$10.00+2,167.6%-66.9%$18.39M$640K-0.4140High Trading VolumeQTTBQ32 Bio2.5603 of 5 stars$1.49+7.2%$12.17+716.6%-92.4%$18.17M$1.16M-0.3039Analyst DowngradePRPHProPhase LabsN/A$0.43flatN/A-88.6%$18.03M$6.77M-0.34130ASBPAspire BiopharmaN/A$0.36+15.1%N/AN/A$17.85MN/A0.00N/AGap UpHigh Trading VolumeGELSGelteqN/A$1.88-1.3%N/AN/A$17.70M$100K0.00N/ANews CoverageCASICASI Pharmaceuticals4.1669 of 5 stars$1.40-0.1%$4.00+184.9%-80.8%$17.27M$28.54M-0.55180LPCNLipocine2.7148 of 5 stars$3.21+2.4%$9.00+180.0%-43.7%$17.12M$11.20M-3.1410MTEXMannatech1.2176 of 5 stars$8.82+4.8%N/A+11.9%$16.75M$117.87M-88.15250 Related Companies and Tools Related Companies Reviva Pharmaceuticals Competitors Hoth Therapeutics Competitors Rallybio Competitors Q32 Bio Competitors ProPhase Labs Competitors Aspire Biopharma Competitors Gelteq Competitors CASI Pharmaceuticals Competitors Lipocine Competitors Mannatech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THAR Stock Alerts